|
Cara Therapeutics, Inc. (Cara) Valation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Cara Therapeutics, Inc. (CARA) Bundle
Gardez un aperçu de votre analyse d'évaluation de votre Cara Therapeutics, Inc. (Cara) avec notre calculatrice DCF de pointe! Préchargé avec des données réelles (CARA), ce modèle Excel vous permet d'ajuster les prévisions et les hypothèses pour déterminer avec précision la valeur intrinsèque de Cara Therapeutics, Inc. (CARA).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 135.1 | 23.0 | 41.9 | 21.0 | 7.1 | 5.0 | 3.6 | 2.5 | 1.8 | 1.3 |
| Revenue Growth, % | 0 | -82.95 | 81.81 | -49.92 | -65.96 | -29.26 | -29.26 | -29.26 | -29.26 | -29.26 |
| EBITDA | 5.6 | -88.2 | -83.8 | -117.7 | -62.6 | -4.0 | -2.8 | -2.0 | -1.4 | -1.0 |
| EBITDA, % | 4.14 | -382.98 | -200.17 | -561.09 | -877.12 | -79.17 | -79.17 | -79.17 | -79.17 | -79.17 |
| Depreciation | 1.0 | 1.6 | 1.7 | .3 | .2 | .2 | .1 | .1 | .1 | .0 |
| Depreciation, % | 0.75139 | 6.75 | 3.99 | 1.24 | 2.69 | 3.08 | 3.08 | 3.08 | 3.08 | 3.08 |
| EBIT | 4.6 | -89.7 | -85.5 | -117.9 | -62.8 | -4.0 | -2.8 | -2.0 | -1.4 | -1.0 |
| EBIT, % | 3.39 | -389.73 | -204.16 | -562.33 | -879.81 | -79.32 | -79.32 | -79.32 | -79.32 | -79.32 |
| Total Cash | 180.9 | 167.0 | 145.4 | 100.8 | 37.9 | 5.0 | 3.6 | 2.5 | 1.8 | 1.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.1 | 1.2 | 4.5 | 4.0 | 4.5 | 1.0 | .7 | .5 | .4 | .3 |
| Account Receivables, % | 1.53 | 5 | 10.64 | 19.16 | 62.98 | 19.86 | 19.86 | 19.86 | 19.86 | 19.86 |
| Inventories | -1.5 | 2.6 | 2.4 | 2.8 | .9 | .4 | .3 | .2 | .1 | .1 |
| Inventories, % | -1.12 | 11.22 | 5.69 | 13.45 | 12.61 | 8.37 | 8.37 | 8.37 | 8.37 | 8.37 |
| Accounts Payable | 4.9 | 5.6 | 9.6 | 11.6 | 1.4 | 1.3 | .9 | .6 | .5 | .3 |
| Accounts Payable, % | 3.62 | 24.43 | 22.94 | 55.24 | 20.09 | 25.26 | 25.26 | 25.26 | 25.26 | 25.26 |
| Capital Expenditure | -.3 | .0 | .0 | -2.4 | -1.0 | -.3 | -.2 | -.1 | -.1 | -.1 |
| Capital Expenditure, % | -0.25836 | -0.16936 | -0.10271 | -11.33 | -14.66 | -5.3 | -5.3 | -5.3 | -5.3 | -5.3 |
| Tax Rate, % | 0.55848 | 0.55848 | 0.55848 | 0.55848 | 0.55848 | 0.55848 | 0.55848 | 0.55848 | 0.55848 | 0.55848 |
| EBITAT | 5.0 | -89.5 | -83.4 | -117.9 | -62.4 | -4.0 | -2.8 | -2.0 | -1.4 | -1.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 10.0 | -90.4 | -80.9 | -118.0 | -72.0 | -.3 | -2.9 | -2.0 | -1.4 | -1.0 |
| WACC, % | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 | 6.1 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -6.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -25 | |||||||||
| Present Terminal Value | -19 | |||||||||
| Enterprise Value | -25 | |||||||||
| Net Debt | -38 | |||||||||
| Equity Value | 13 | |||||||||
| Diluted Shares Outstanding, MM | 46 | |||||||||
| Equity Value Per Share | 0.28 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real CARA financials.
- Real-World Data: Historical data and forward-looking estimates (as displayed in the highlighted cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Cara Therapeutics' valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive CARA Data: Pre-filled with Cara Therapeutics’ historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, margins, WACC, tax rates, and capital expenditures to fit your analysis.
- Dynamic Valuation Model: Instant updates to Net Present Value (NPV) and intrinsic value based on your customized inputs.
- Scenario Testing: Develop multiple forecast scenarios to explore various valuation possibilities.
- User-Friendly Design: Intuitive, structured layout suitable for both professionals and newcomers.
How It Works
- Download the Template: Get instant access to the Excel-based CARA DCF Calculator.
- Input Your Assumptions: Adjust yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically updates Cara Therapeutics' intrinsic value.
- Test Scenarios: Simulate different assumptions to evaluate potential valuation changes.
- Analyze and Decide: Use the results to guide your investment or financial analysis.
Why Choose This Calculator?
- User-Friendly Interface: Perfect for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters to align with your financial assessments.
- Real-Time Valuation: Observe immediate updates to Cara Therapeutics' valuation as you tweak inputs.
- Preloaded Data: Comes with Cara Therapeutics' actual financial metrics for swift evaluations.
- Endorsed by Experts: Favored by investors and analysts for making educated choices.
Who Should Use This Product?
- Investors: Evaluate Cara Therapeutics’ valuation prior to making stock transactions.
- CFOs and Financial Analysts: Enhance valuation procedures and assess financial forecasts.
- Startup Founders: Understand how established biotech companies like Cara Therapeutics are appraised.
- Consultants: Provide comprehensive valuation reports for clients in the healthcare sector.
- Students and Educators: Utilize real-world data to practice and instruct on valuation methodologies.
What the Template Contains
- Historical Data: Includes Cara Therapeutics’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Cara Therapeutics’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Cara Therapeutics’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.